Review article: the new concept of interventional heart failure therapy--part 1: electrical therapy, treatment of CAD, fluid removal, and ventricular support.

abstract：BACKGROUND:Brief periods of reocclusion (postconditioning) during early reperfusion reduce myocardial infarct size. Whether postconditioning has an effect on lethal ventricular arrhythmias independent of infarction in an in-vivo regional ischemia model is unknown. The purpose of this study was to determine if postcondi...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kloner RA,Dow J,Bhandari A

更新日期：2006-03-01 00:00:00

abstract：:The aim of this study was to demonstrate whether HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides), was effective in improving levels of plasma free radicals (PFRs) in patients with chronic venous insufficiency (CVI) and venous microangiopathy. Patients were randomized into the treatment group, which received o...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Cesarone MR,Incandela L,DeSanctis MT,Belcaro G,Dugall M,Acerbi G

更新日期：2002-01-01 00:00:00

abstract：:Homing of cardiac myosin-specific CD4-positive T cells into the myocardium is the initial pathologic event of experimental autoimmune myocarditis (EAM). Subsequently, various bystander inflammatory cells are recruited into the myocardium crossing vascular endothelial cell walls. Sulfated polysaccharide fucoidan binds ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Tanaka K,Ito M,Kodama M,Tomita M,Kimura S,Hoyano M,Mitsuma W,Hirono S,Hanawa H,Aizawa Y

更新日期：2011-03-01 00:00:00

abstract：INTRODUCTION:Pulmonary hypertension (PH) is a potentially deadly disease for infants and adults with few existing medical interventions and no cure. In PH, increased blood pressure in the pulmonary artery eventually leads to heart failure. Fasudil, an antagonist of Rho-kinase, causes vasodilation leading to decreased s...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hanson SFL,Terry MH,Moretta DT,Power GG,Wilson SM,Alam F,Ahsan F,Blood AB,Giri PC

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:We investigated whether the cardioprotective, volatile gas anesthetic agent, isoflurane, could improve survival and organ function from hemorrhagic shock in an experimental rat model, compared to standard nonvolatile anesthetic agent ketamine/xylazine. METHODS:Sprague Dawley rats (both genders) were randomi...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Dai W,Shi J,Carreno J,Kloner RA

更新日期：2020-07-01 00:00:00

abstract：:Atrial fibrillation has recently come into clinical and research focus. In particular, ventricular rate control has been carefully compared with atrial rhythm control. Additionally, the recent discovery of atrial stunning has initiated clinical and research interest in atrial remodeling. Atrial fibrillation is more li...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Opie LH

更新日期：2003-06-01 00:00:00

abstract：:Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist remains a mainstay in the prevention of ischemic events following coronary stent placement. Significant controversy exists regarding the optimal management of high platelet reactivity despite antiplatelet therapy; however this finding has been cons...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Weeks PA,Sieg A,Paruthi C,Rajapreyar I

更新日期：2015-07-01 00:00:00

abstract：:Beta-Adrenergic blockers have a wide spectrum of action for controlling cardiac arrhythmias that is larger than initially thought. Data from the past several decades indicate that, as an antiarrhythmic class, beta-blockers remain among the very few pharmacologic agents that reduce the incidence of sudden cardiac death...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Singh BN

更新日期：2005-06-01 00:00:00

abstract：:BACKGROUND: Digoxin improves baroreflex function and reduces neurohumoral activation in severe heart failure, but it is uncertain how digoxin affects ventricular remodeling and progression to left ventricular dysfunction. In addition, the effect of digoxin in in vitro beta-adrenoceptor density and function, and contra...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sullebarger JT,D'Ambra PM,Clark LC,Thanikarry L,Fontanet HL

更新日期：1998-10-01 00:00:00

abstract：BACKGROUND:Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. DESIGN:The present study was performed to evaluate whether combination therapy of cl...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Niu Q,Wang Z,Zhang Y,Wang J,Zhang P,Wang C,Yin X,Hou Y

更新日期：2017-03-01 00:00:00

abstract：:BACKGROUND: Acute myocarditis can progress to chronic heart muscle disease and cardiomyopathy. In the coxsackievirus B(3) (CB(3)) mouse model of myocarditis, early administration of captopril, an angiotensin-converting enzyme (ACE) inhibitor, ameliorated histopathological changes in inflammation, necrosis, and calcifi...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Reyes MP,Khatib R,Khatib G,Ho KL,Smith F,Kloner RA

更新日期：1998-01-01 00:00:00

abstract：BACKGROUND:Renalase is a protein that can regulate sympathetic nerve activity by metabolizing catecholamines, while redundant catecholamines are thought to contribute to atherosclerosis (As). Catecholamine release can be facilitated by angiotensin (Ang) II by binding to Ang II type 1 (AT1) receptors. Valsartan, a speci...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Zhou M,Ma C,Liu W,Liu H,Wang N,Kang Q,Li P

更新日期：2015-09-01 00:00:00

abstract：:BACKGROUND: Clinical trials have shown that the use of lipid-lowering agents in postmyocardial infarction (MI) patients reduces rates of subsequent coronary events, reduces coronary artery bypass surgery rates, and improves survival. Physician decisions to prescribe lipid-lowering drugs is influenced by a number of pa...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Khan M,Mukkamala A,Taylor DK,Espinosa A,Duff J

更新日期：1998-07-01 00:00:00

abstract：:The effects of nitric oxide (NO) and noradrenergic activation in the posterior hypothalamus on arterial pressure tolerance induced by subcutaneous injection of nitroglycerin (NTG) was investigated in anesthetized Sprague-Dawley rats. Intravenous injections of NTG (3, 10, and 30 microg/kg) and sodium nitroprusside (1, ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Guettler DL,Ma SX

更新日期：2008-06-01 00:00:00

abstract：:Recently, cyclooxygenase-2 (COX-2) inhibitors (coxibs), a class of drugs intended to be painkillers, have created unprecedented controversy because of their cardiovascular risk profile. The controversy has affected the patients, health-care providers, the Food and Drug Administration, and the manufacturers of these ag...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Schrör K,Mehta P,Mehta JL

更新日期：2005-06-01 00:00:00

abstract：BACKGROUND:Omapatrilat has potent enzymatic inhibitory effects on the angiotensin-converting enzyme and neutral endopeptidase. The prolonged effects of this inhibition on systemic and regional hemodynamics, cardiovascular mass, and hydroxyproline concentration in spontaneously hypertensive rats were studied. The contri...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Varagic J,Susic D,Slama M,Frohlich ED

更新日期：2003-06-01 00:00:00

abstract：BACKGROUND:epidemiologic studies indicate that elevated heart rate (HR) is an independent risk factor for mortality and morbidity in patients (pts) with chronic heart failure (CHF). Clinical trials with β-blockers suggest that HR reduction is an important mechanism of their benefit in pts with stable CHF. Pharmacologic...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sarullo FM,Fazio G,Puccio D,Fasullo S,Paterna S,Novo S,Di Pasquale P

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:Dystrophin-deficient cardiomyopathy is a growing clinical problem without targeted treatments. We investigated whether nicorandil promotes cardioprotection in human dystrophin-deficient induced pluripotent stem cell (iPSC)-derived cardiomyocytes and the muscular dystrophy mdx mouse heart. METHODS AND RESULT...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Afzal MZ,Reiter M,Gastonguay C,McGivern JV,Guan X,Ge ZD,Mack DL,Childers MK,Ebert AD,Strande JL

更新日期：2016-11-01 00:00:00

abstract：:Prior studies have suggested that intravenous diltiazem reduces the probability of spontaneous conversion of atrial fibrillation (AF) to sinus rhythm in the electrophysiology laboratory and in patients with postoperative AF. Whether diltiazem exerts the same effect in patients presenting to the emergency department (E...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hassan S,Slim AM,Kamalakannan D,Khoury R,Kakish E,Maria V,Ahmed S,Pires LA,Kronick SL,Oral H,Morady F

更新日期：2007-09-01 00:00:00

abstract：:BACKGROUND: Conventional microelectrode techniques were used to compare the concentration-dependent effects of vesnarinone (0.1-100 µM) and amrinone (1 µM-1 mM) on action potential duration (APD) and developed force in both isolated dog ventricular trabeculae and Purkinje strands. METHODS AND RESULTS: Both drugs incre...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lathrop DA,Nánási PP,Varró A,Schwartz A

更新日期：1996-04-01 00:00:00

abstract：:Antiplatelet therapy is indicated for the treatment of ischemic stroke or transient ischemic attack (TIA). Aspirin reduces subsequent occlusive vascular events, including recurrent stroke, by about 25%. In such patients, clopidogrel has been evaluated in an effort to further reduce risk. In the Management of Atherothr...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gorelick P,Sechenova O,Hennekens CH

更新日期：2006-12-01 00:00:00

abstract：:Qiliqiangxin (QL), a traditional Chinese medicine, has been shown to be beneficial for chronic heart failure. However, whether QL can also improve endothelial cell function in diabetic rats remains unknown. Here, we investigated the effect of QL treatment on endothelial dysfunction by comparing the effect of QL to tha...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Chen F,Wu JL,Fu GS,Mou Y,Hu SJ

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:Although a gradual increase in heart rate (HR) during dobutamine stress testing (DST) is desired, few data exists regarding whether this is similarly achieved in patients of widely varying body mass index (BMI). Whether difference in BMI contributes to variation in the hemodynamic and symptomatic response to...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kittipovanonth M,Bernheim AM,Scott CG,Barnes ME,Shub C,Pellikka PA

更新日期：2011-06-01 00:00:00

abstract：INTRODUCTION:Recent evidence suggests that transcriptional reprogramming is involved in the pathogenesis of cardiac remodeling (cardiomyocyte hypertrophy and fibrosis) and the development of heart failure. 5-Azacytidine (5aza), an inhibitor of DNA methylation approved for hematological malignancies, has previously demo...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Russell-Hallinan A,Neary R,Watson CJ,Baugh JA

更新日期：2020-12-02 00:00:00

abstract：:The antiarrhythmic potential of postconditioning in in vivo models remains poorly defined. We compared the effects of pre- and postconditioning on ventricular arrhythmogenesis against controls with and without reperfusion. Wistar rats (n = 40, 269 ± 3 g) subjected to ischemia (30 minutes)--reperfusion (24 hours) were ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kolettis TM,Vilaeti AD,Tsalikakis DG,Zoga A,Valenti M,Tzallas AT,Papalois A,Iliodromitis EK

更新日期：2013-07-01 00:00:00

abstract：:Catestatin (CST), which is emerging as a novel cardiac modulator, can protect the heart against excessive sympathetic drive in hypertensive cardiomyopathy. The aim of this study is to investigate whether exogenous CST decreases excessive cardiac sympathetic drive and improves autonomic function and exerts cardioprotec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wang D,Liu T,Shi S,Li R,Shan Y,Huang Y,Hu D,Huang C

更新日期：2016-11-01 00:00:00

abstract：BACKGROUND:Whether cardioprotection induced by the angiotensin II (AngII) type 2 receptor (AT(2)R) antagonist PD123,319 (PD) after ischemia-reperfusion (IR) is influenced by the concentration of PD, presence of AngII, timing of exposure, or inhibition of proton production from glucose metabolism is not known. METHODS ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ford WR,Clanachan AS,Jugdutt BI

更新日期：2000-07-01 00:00:00

abstract：:Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Narechania S,Torbic H,Tonelli AR

更新日期：2020-03-01 00:00:00

abstract：:Despite initial promising reports that anti-inflammatory properties of cycloxygenase-2 (COX-2) inhibitors may confer anti-atherosclerosis effects and stabilize the atherosclerotic plaque, subsequent data from long-term clinical trials have shown that selective COX-2 inhibitors are associated with increased risk of car...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Salinas G,Rangasetty UC,Uretsky BF,Birnbaum Y

更新日期：2007-06-01 00:00:00

abstract：BACKGROUND:Allogeneic cardiosphere-derived cells (CDCs) exert cardioprotective effects when administered intracoronarily after reperfusion in animal models of acute myocardial infarction (AMI). The "no-reflow" phenomenon develops rapidly post-reperfusion and may undermine the efficacy of cell therapy, due to poor cell ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sousonis V,Sfakianaki T,Ntalianis A,Nanas I,Kontogiannis C,Aravantinos D,Kapelios C,Katsaros L,Nana M,Sampaziotis D,Sanoudou D,Papalois A,Malliaras K

更新日期：2021-01-01 00:00:00